Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec Reports Strong Earnings Thanks to Robust Sales Of Flagship Products

This article was originally published in The Pink Sheet Daily

Executive Summary

With former Exelixis chief George Scangos in the house and hinting at cultural changes, the Cambridge, Mass. biotech beat estimates with strong sales of Avonex and Rituxan. Progress in testing for the deadly JC virus could soon give Tysabri sales a lift.
Advertisement

Related Content

Novartis Gilenya Approved With Advisory Panel-Enhanced REMS
Novartis Gilenya Approved With Advisory Panel-Enhanced REMS
First Deal Of Scangos Era Brings Phase II ALS Candidate To Biogen Idec
First Deal Of Scangos Era Brings Phase II ALS Candidate To Biogen Idec
Biogen Makes Counterintuitive Move To Tap Exelixis's Scangos As CEO
Biogen Makes Counterintuitive Move To Tap Exelixis's Scangos As CEO
Agreement Averts Another Proxy Fight Between Biogen Idec, Icahn

Topics

Advertisement
UsernamePublicRestriction

Register

PS070927

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel